Final rule on certified EHR review, oversight released by ONC

The Office of the National Coordinator for Health IT (ONC) has released the final rule on its Health IT Certification Program, focusing on “reliability, transparency, accountability and safety” of certified electronic health records (EHRs).

“More transparency and accountability in health IT is good for consumers, physicians and hospitals,” National Coordinator for Health IT Vindell Washington, MD, said in a statement. “Today’s final rule strengthens the program by ensuring that certified health IT helps clinicians and individuals use and exchange electronic health information safely and reliably.” 

The rule focuses on three areas:

  • Reviewing products: The rule sets up the review process for certified health IT products and allows ONC to take action when there are potential risks for “public health and safety” or practical challenges for authorized certification bodies are present. The rule does include an appeals process for health IT developers which have their certifications suspended or terminated by ONC.
  • Authorization and oversight: The rule “establishes a process for ONC to authorize and oversee accredited testing laboratories to align with ONC’s existing oversight” of authorized certification bodies. The change should allow the agency “to quickly, directly, and precisely address testing and performance issues.” ONC will also help developers craft corrective action plans to be approved by the agency to “remedy any nonconformities” in their products.
  • Transparency: The surveillance results of certified health IT products will be made available to the public on a quarterly basis through an online certified IT product list.

ONC said the goal of the updates to the certification program is to support physicians and hospitals which use certified EHR technology, as well as deal with the “rapid pace of innovation” in the health IT market.

In its initial reaction to the rule, the College of Healthcare Information Management Executives (CHIME) supported the efforts to make surveillance reports more readily accessible.

“CHIME appreciates that steps that the agency is taking to increase transparency of health IT performance,” the group’s statement said. “Hospitals and clinicians must have confidence that the products they purchase work as intended and do not pose a significant risk to patient safety or public health.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.